Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Business Wire•30/09/2026•19:12 ET
0
Key Highlights
- ➤Adicet Bio (ACET) grants inducement options for 725 common shares
- ➤$7.14 exercise price equals Adicet Bio’s September 30 closing price
- ➤Option vests over four years, subject to continued employment
- ➤Award issued under Adicet Bio’s 2022 Inducement Plan
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on September 30, 2026.
Get started
Create a free account to read the full story.